Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/45742
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study |
Autor: | Lahuerta, Juan José; Mateos, Maria Victoria; San Miguel, Jesús F. CSIC ORCID | Palabras clave: | Multiple myeloma Stem cell transplantation Conditioning regimen |
Fecha de publicación: | 1-nov-2010 | Editor: | Ferrata Storti Foundation | Citación: | Haematologica 95(11): 1913-1920 (2010) | Resumen: | Background The aim of this study was to compare the long-term safety and efficacy of oral busulfan 12 mg/kg plus melphalan 140 mg/m2 and melphalan 200 mg/m2 as conditioning regimens for autologous stem cell transplantation in newly diagnosed patients with multiple myeloma in the GEM2000 study. Design and Methods The first 225 patients received oral busulfan 12 mg/kg plus melphalan 140 mg/m2; because of a high frequency of veno-occlusive disease, the protocol was amended and a further 542 patients received melphalan 200 mg/m2. Results Engraftment and hospitalization times were similar in both groups. Oral busulfan 12 mg/kg plus melphalan 140 mg/m2 resulted in higher transplant-related mortality (8.4% versus 3.5%; P=0.002) due to the increased frequency of veno-occlusive disease in this group. Response rates were similar in both arms. With respective median follow-ups of 72 and 47 months, the median progression-free survival was significantly longer with busulfan plus melphalan (41 versus 31 months; P=0.009), although survival was similar to that in the melphalan 200 mg/m2 group. However, access to novel agents as salvage therapy after relapse/progression was significantly lower for patients receiving busulfan plus melphalan (43%) than for those receiving melphalan 200 mg/m2 (58%; P=0.01). Conclusions Conditioning with oral busulfan 12 mg/kg plus melphalan 140 mg/m2 was associated with longer progression-free survival but equivalent survival to that achieved with melphalan 200 mg/m2 but this should be counterbalanced against the higher frequency of veno-occlusive disease-related deaths. This latter fact together with the limited access to novel salvage therapies in patients conditioned with oral busulfan 12 mg/kg plus melphalan 140 mg/m2 may explain the absence of a survival difference. Oral busulfan was used in the present study; use of the intravenous formulation may reduce toxicity and result in greater efficacy, and warrants further investigation in myeloma patients. | Descripción: | 27 páginas, 3 figuras, 2 tablas.-- et al. | Versión del editor: | http://dx.doi.org/10.3324/haematol.2010.028027 | URI: | http://hdl.handle.net/10261/45742 | DOI: | 10.3324/haematol.2010.028027 | ISSN: | 0390-6078 | E-ISSN: | 1592-8721 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
10.3324-haematol.2010.028027.pdf | 650,11 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
27
checked on 24-mar-2024
SCOPUSTM
Citations
100
checked on 21-mar-2024
WEB OF SCIENCETM
Citations
90
checked on 29-feb-2024
Page view(s)
378
checked on 28-mar-2024
Download(s)
351
checked on 28-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.